GlassScriptPhysician profile
Lance Mcleroy
NPI 1508279332
$1,975.48
in general payments reported to CMS, 2019-2025
15 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $196 · 2021: $622 · 2022: $360 · 2023: $355 · 2024: $227 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $886.44 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.82 | 2020-2023 | Xifaxan |
| Janssen Biotech, INC. | $226.14 | 2020-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $89.14 | 2021-2024 | |
| Pfizer INC. | $89.12 | 2021-2023 | |
| Celgene Corporation | $74.32 | 2022-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $63.14 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.43 | 2023-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $33.92 | 2021-2022 | |
| Amgen INC. | $33.14 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $16.36 | 2020 | |
| Genzyme Corporation | $15.54 | 2023 | |
| Redhill Biopharma INC. | $13.77 | 2021 | |
| Intra-Sana Laboratories | $10.72 | 2022 | |
| Organon LLC | $8.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Mcleroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.